ResearcherStony Brook UniversityActive in the last 2 years

Stephen D’Amico

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0004-6425-7822; OpenAlex author ID A5066268678. Sources: OpenAlex.

Their work

Papers: 2 (first author 1, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2021: 1 paper · 2022: none · 2023: none · 2024: 1 paper

Papers 2

STAT3 is a genetic modifier of TGF-beta induced EMT in KRAS mutant pancreatic cancer. Co-author DOI 10.7554/elife.92559 ↗
KRAS drives immune evasion in a genetic model of pancreatic cancer. First author DOI 10.1038/s41467-021-21736-w ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Nancy C. Reich Marshall · 2 shared papers, 2021–2024 · strength 0.45
- Paper STAT3 is a genetic modifier of TGF-beta induced EMT in KRAS mutant pancreatic cancer. DOI 10.7554/elife.92559 ↗
- Paper KRAS drives immune evasion in a genetic model of pancreatic cancer. DOI 10.1038/s41467-021-21736-w ↗
Irene Ischenko · 1 shared paper, 2021 · strength 0.14
- Paper KRAS drives immune evasion in a genetic model of pancreatic cancer. DOI 10.1038/s41467-021-21736-w ↗
Michael J. Hayman · 1 shared paper, 2021 · strength 0.14
- Paper KRAS drives immune evasion in a genetic model of pancreatic cancer. DOI 10.1038/s41467-021-21736-w ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.